期刊文献+

雷帕霉素对人肝癌裸鼠原位移植瘤生长的抑制作用 被引量:13

Rapamycin inhibited the growth of hepatocellular carcinoma in nude mice
原文传递
导出
摘要 目的探讨雷帕霉素对人肝癌裸鼠原位移植瘤生长的影响及其机制。方法建立人肝癌棵鼠肝原位移植瘤模型32只,随机分为空白对照组、FK506组、雷帕霉素常规剂量组和高剂量组。用药两周后观察肿瘤体积的变化,免疫组织化学法检测肝癌组织中增殖细胞核抗原(PCNA)、血管内皮细胞生长因子(VEGF)的表达。结果对照组、FK506组、雷帕霉素常规剂量组、高剂量组平均肿瘤体积分别为:(310.15±40.16)、(605.59±116.23)、(99.19±15.27)、(151.61±27.81) mm3。与对照组相比,雷帕常规剂量组及高剂量组肿瘤体积明显缩小,PCNA、VEGF的表达均显著下调(P<0.01);FKS06组肿瘤体积与对照组相比明显增大,差异有统计学意义(P<0.01),PC- NA、VEGF的表达与对照组相比差异无统计学意义(P>0.01)。结论雷帕霉素具有显著抑制肝癌生长的作用,其机制可能是抑制了肝癌细胞的恶性增殖及VEGF的产生。 Objective To study the antitumor effort of rapamycin on hepatocellular carcinoma and the relevant mechanism. Methods Nude mice bearing orthotopic xenografty human HCC were randomly divided into 4 groups: control group, tacrolimus group, rapamycin group, rapamycin high dose group. The effect on the tumor growth was evaluated using tumor volume after 2 weeks. PCNA and VEGF expression in liver cancer tissue was detected by using immunohistochemistry. Results The tumor volume was (310.15 ± 40.16), (605.59 ± 116.23), (99.19 ± 15.27), (151.61 ± 27.81) mm^3 in control, tacrolimus, rapamycin and rapamycin high dose groups respectively. The tumor volume was significandy decreased in rapamycin group and rapamycin high dose group, but increased in tacrolimus group as compare with control group. The expression of PCNA and VEGF was downregulated in rapamycin group and rapamycin high dose group as compare with control group. Conclusion The growth of HCC in the nude mice was inhibited when the animals were exposed to rapamycin but enhanced when exposed to tacrolimus. The antitumor effort of rapamycin attributes to the retardation of tumor cell growth and the downregulation of VEGF expression probably.
出处 《中华实验外科杂志》 CAS CSCD 北大核心 2006年第4期560-562,共3页 Chinese Journal of Experimental Surgery
关键词 雷帕霉索 他克莫司 肝细胞 Rapamycin Tacrolimus Carcinoma, hepatocellular
  • 相关文献

参考文献9

  • 1Gudrun EK,Joachim A,Maekus G,et al.Rapamycin protects allografts while simultaneously attacking tumor in immunosuppressed mice.Tranaplantation,2004,1319-1326.
  • 2Huang S,Houghton PJ.Inhibitors of mammalian target of rapamycin as novel antitumor agents:from bench to clinic.Curr Opinion Invest Drugs,2002,3:295-304.
  • 3Guba M,yon Breitenbuch P,Steinbauer M,et al.Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis:involvement of vascular endothelial growth factor.Nat Med,2002,8:128.
  • 4郜永顺,陈孝平,李开艳,吴在德.人肝癌组织多药耐药特性裸鼠模型的建立[J].中华实验外科杂志,2005,22(4):492-493. 被引量:7
  • 5Raught B,Gingras A C,Sonenberg N.The target of rapamycin (TOR)proteins.PNAS,2001,98:7037-7044.
  • 6Hidalgo M,Rowinsky EK.The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.Oncogene,2000,19:6680-6686.
  • 7Benito AI,Frulong T,Martin PJ,et al.Sirolimus (rapamycin) for the treatment of steroid-refractory acute graft-versus-host disease.Transplatation,2001,72:1924-1929.
  • 8卢绮萍,吴在德,王伟,田磊,李德忠.Rxa对L02细胞增殖的细胞周期分析和对Ki-67、Cyclin D1、PCNA蛋白表达的影响[J].中华实验外科杂志,1999,16(6):512-514. 被引量:8
  • 9Luan FL,Ding R,Sharma VK,et al.Rapamycin is an effective inhibitor of human renal cancer metastasis.Kidney Int,2003,63:917.

二级参考文献7

共引文献13

同被引文献90

引证文献13

二级引证文献80

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部